Boston Scientific reports Q2 2026 net sales $5.442 billion
GAAP net income rose to $907 million, adjusted EPS $0.86 beat guidance, and full-year organic growth guided at 5-6%.
See the latest news and media coverage for Boston Scientific. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global medical device manufacturer
bostonscientific.comLast updated
In short: Boston Scientific reported steady 2026 financial growth while implementing an $800 million restructuring plan and managing product recalls.
GAAP net income rose to $907 million, adjusted EPS $0.86 beat guidance, and full-year organic growth guided at 5-6%.
The eCoin System is a tibial nerve stimulator for urge urinary incontinence.
The SEISMIQ 4CE catheter met primary safety and effectiveness endpoints for treating severe coronary artery disease.
The ASR with JPMorgan will repurchase 80% of the $2 billion upfront, settled by June 2026, accretive to EPS.
Boston Scientific has confirmed that its Costa Rican operation forms part of a global restructuring program that sets aside as much as $300 million for...
Company officials are mum on details of their restructuring plan, but it could affect operations at...
Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442...
Boston Scientific (BSX) Q2 2026 earnings call: Q2 results, lowered 2026 guidance, WATCHMAN/EP pressures, and $500M restructuring plan.
Track Boston Scientific and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Boston Scientific and other trending companies.